Dexcom Stelara™ CGM Sensor Clears Six-Month Wear with 8.5% Mean MARD in Pivotal Trial

Dexcom (NASDAQ: DXCM) has commercially launched Stelara™, its newest continuous glucose monitoring system, following FDA 510(k) clearance last month. The headline feature is straightforward: Stelara lasts 180 days — six times longer than the Dexcom G7 sensor it replaces in the product hierarchy — before requiring replacement.

The durability gain comes from a redesigned biocompatible polymer housing and a dual-analyte sensing chemistry that measures both glucose and interstitial fluid conductivity to compensate for sensor drift over time. In the 380-patient DEX-186 pivotal trial, Stelara achieved a mean absolute relative difference (MARD) of 8.5% against high-frequency blood glucose reference measurements, an accuracy threshold that places it among the most precise CGM systems commercially available and well below the 10% threshold generally considered clinically acceptable for insulin-dosing decisions.

For patients with type 2 diabetes — a population Dexcom has increasingly targeted after years focused primarily on the type 1 market — the six-month sensor life substantially reduces the cost-per-day burden. At current U.S. pricing, Stelara's per-day sensor cost lands approximately 35% below the G7 on a prorated basis, making it more competitive with Abbott's FreeStyle Libre 3 (which offers a 14-day sensor) for patients and payers evaluating total cost of CGM programs.

Stelara communicates with Dexcom's updated Clarus™ mobile app and integrates with the Tidepool, Glooko, and Medtronic CareLink ecosystems. A compatible Bluetooth transmitter module is embedded directly in the sensor body, eliminating the need for a separate transmitter puck that characterized earlier Dexcom generations. The sensor is currently indicated for adults with type 2 diabetes; a pediatric indication (ages 2–17) is under FDA review with a decision expected by late 2027.